350 Eli Lilly and Company $LLY Shares Purchased by Guardian Financial Partners LLC

Guardian Financial Partners LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 63.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 905 shares of the company’s stock after purchasing an additional 350 shares during the quarter. Guardian Financial Partners LLC’s holdings in Eli Lilly and Company were worth $1,048,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of LLY. Coastal Bridge Advisors LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at about $2,959,000. Birinyi Associates Inc. grew its stake in Eli Lilly and Company by 32.6% in the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after acquiring an additional 359 shares in the last quarter. Mosaic Family Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after acquiring an additional 1,430 shares during the period. Heritage Investors Management Corp increased its position in shares of Eli Lilly and Company by 6.5% during the third quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock worth $13,624,000 after acquiring an additional 718 shares during the period. Finally, Capital Investment Advisors LLC raised its stake in shares of Eli Lilly and Company by 51.3% during the third quarter. Capital Investment Advisors LLC now owns 44,851 shares of the company’s stock valued at $51,896,000 after acquiring an additional 15,214 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo met the primary endpoint in a Phase 3 trial for obstructive sleep apnea, reducing breathing interruptions by up to an average of 44%. Lilly plans to seek FDA approval for the additional use by year-end, which could broaden the pill’s commercial opportunity beyond weight loss. Reuters article
• Positive Sentiment: Jefferies raised its price target to $1,700 and maintained a Buy rating, signaling continued analyst confidence in Lilly’s prospects. Jefferies price target
• Positive Sentiment: Lilly’s agreement with Hims & Hers and a similar arrangement with LifeMD expands digital access to its branded obesity medicines, including Zepbound and Foundayo. Hims’ share-price decline following its own disappointing results appears company-specific; coverage reported Lilly holding steady. Yahoo Finance article
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden, potentially permanent vision loss. The class-wide warning could raise safety concerns for patients and investors, though the condition is rare. CNBC article

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,432.60 on Wednesday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a 50 day moving average price of $1,225.57 and a 200-day moving average price of $1,104.56. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,453.00. The stock has a market capitalization of $1.35 trillion, a PE ratio of 46.50, a PEG ratio of 1.69 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue was up 38.6% compared to the same quarter last year. During the same period last year, the company posted $7.02 earnings per share. Equities analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Analyst Ratings Changes

A number of analysts recently issued reports on LLY shares. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a report on Monday. Sanford C. Bernstein restated an “outperform” rating and set a $1,450.00 price objective on shares of Eli Lilly and Company in a report on Monday, October 26th. HSBC raised their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Leerink Partners lifted their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research report on Wednesday, October 21st. Finally, Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.